Madlen Jentzsch

36PUBLICATIONS
100CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersRegenerative medicine (incl. stem cells)Medical mycologyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (36)

|Apr 06, 2026
Body composition predicts poor outcomes and reveals immunometabolic dysfunction via single-cell profiling in anti-BCMA CAR T-treated myeloma.

Thomas C Wiemers, Michael Rade, Nora Grieb

|Jul 21, 2025
Gemtuzumab ozogamicin in first-line treatment of CBF-AML: insights from a retrospective multi-center analysis.

Julian Ronnacker, Philippe J Muller, Jan-Henrik Mikesch

|Jun 16, 2025
Prognostic significance of PET/CT for CAR T cell therapy in relapsed/refractory multiple myeloma.

Patrick Born, David Fandrei, Song Yau Wang

|Mar 12, 2025
Allogeneic stem cell transplantation for MDS-clinical issues, choosing preparative regimens and outcome.

Lara Bischof, Jule Ussmann, Uwe Platzbecker

|Jan 15, 2025
Prognostic impact of expression of CD2, CD25, and/or CD30 in/on mast cells in systemic mastocytosis: a registry study of the European Competence Network on Mastocytosis.

Axel Rüfer, Henning Nilius, Olivier Hermine

|Oct 23, 2024
Bispecific Antibodies as Bridging to BCMA CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma.

David Fandrei, Sabine Seiffert, Michael Rade

Pageof 6

Frequent Collaborators

23 joint publications

Sebastian Schwind

21 joint publications

Vladan Vucinic

15 joint publications

Klaus Metzeler

15 joint publications

Uwe Platzbecker